Opinion: Racing Toward Invention

A newly instated patent law discriminates against academics and small biotechs.

Written byGeorge Lewis
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

Seal of the United States Patent and Trademark OfficeWIKIMEDIA, US GOVERNMENTThe introduction of the Leahy-Smith America Invents Act (AIA) on March 16, 2013, has already begun to shape the patent process for a nation of entrepreneurs, scientists, and innovators. The law replaces the former “first to invent” declaration of ownership with “first to file” for an issued patent. In other words, it doesn’t matter who had the idea first, only who brought that idea to the attention of the US Patent and Trademark Office (USPTO).

The controversial law has stirred great debate concerning how this shifting process reflects our nation’s bias toward corporations over smaller businesses and independent or university-affiliated scientists. No doubt, the first-to-file law will create a race to the USPTO for big businesses and independent innovators with sufficient capital to usher a product through the patent filing process, which costs between $7,000 and $10,000. But what about small biotechs and academics without adequate funding? Is the new law killing the American Dream?

Before the AIA, startup companies had a year after public display to file for their patent. That year provided them the opportunity to raise funds and awareness and gather the needed legal team to properly file with the USPTO. Currently, however, those without the resources ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here
Illustration of a developing fetus surrounded by a clear fluid with a subtle yellow tinge, representing amniotic fluid.
January 2026

What Is the Amniotic Fluid Composed of?

The liquid world of fetal development provides a rich source of nutrition and protection tailored to meet the needs of the growing fetus.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Skip the Wait for Protein Stability Data with Aunty

Skip the Wait for Protein Stability Data with Aunty

Unchained Labs

Products

Sino Biological Logo

Sino Biological's Launch of SwiftFluo® TR-FRET Kits Pioneers a New Era in High-Throughout Kinase Inhibitor Screening

SPT Labtech Logo

SPT Labtech enables automated Twist Bioscience NGS library preparation workflows on SPT's firefly platform

nuclera logo

Nuclera eProtein Discovery System installed at leading Universities in Taiwan

Brandtech Logo

BRANDTECH Scientific Introduces the Transferpette® pro Micropipette: A New Twist on Comfort and Control